Sign in

Cristina Popa

@nephroseeker.medsky.social
3K followers 1.1K following 2.1K posts

🩺 Nephrologist = kidney philosopher 📜History lover 🕊️ Aspiring to be better. Freethinker 📍 #NephJC editor-in-chief 📍@KIreportsbsky.social 📍ERAkidney #ERA26 social media co-leader #NephSky #MedSky

PostsRepliesMedia
Reposted by Cristina Popa
kireports.bsky.social @kireports.bsky.social · 17/09/2026
1/ HELLP syndrome is usually lumped with #preeclampsia as “the same disease”. This nationwide French study (CONCEPTION) shows that isolated PE (iPE) & PE-HELLP actually diverge in risk factors AND outcomes Why does it matter?
132
Cristina Popa @nephroseeker.medsky.social · 17/09/2026
Preeclampsia and PE-HELLP are often grouped as the same disease, but are they? New nationwide French data from CONCEPTION show distinct risk factors and outcomes, raising a key question: do they carry the same long-term cardiovascular and kidney risk? #Nephsky
031
Reposted by Cristina Popa
kireports.bsky.social @kireports.bsky.social · 09/09/2026
1/ 🚨Tweetorial Alert🚨 Hey #NephSky! Welcome to a 🆕 #skeetorial brought to you by @KIReports @ISNkidneycare. Please also check out www.kireportscommunity.org educational #blogposts. FOLLOW US!
155
Reposted by Cristina Popa
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 15/09/2026
It’s official - EASiKidney - one of the largest kidney trials at ~ 15000 is terminated early www.boehringer-ingelheim.com/human-health... A setback for ASI in CKD (they are going strong in hypertension of course)
boehringer-ingelheim.com
4105
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 14/09/2026
⏳ Just a bit over one month until #KidneyWk And yes... the legendary #NephJC party is happening again 🎉 🩵Join us, meet the crew, and meet people from across the world 👇Grab your ticket and come be part of the magic www.nephjc.com/news/2026/9/...
nephjc.com
2026 NephJC Night in Denver — NephJC
On FRIDAY night, October 23rd, NephJC will host another legendary NephJC Night during ASN Kidney Week
042
Reposted by Cristina Popa
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 13/09/2026
You want a ticket to the hottest event of #KidneyWk? www.nephjc.com/news/2026/9/... Consider a donation to the fall #NephJC pledge drive
nephjc.com
2026 NephJC Night in Denver — NephJC
On FRIDAY night, October 23rd, NephJC will host another legendary NephJC Night during ASN Kidney Week
044
Cristina Popa @nephroseeker.medsky.social · 10/09/2026
#NephJC helped me find my voice and my people- a global community I'm proud to be part of. We can only continue this work with your support 🩵 Donate to keep the magic going 🪄✨
021
Cristina Popa @nephroseeker.medsky.social · 10/09/2026
#NephJC helped me find my voice and my people- a global community I'm proud to be part of. We can only continue this work with your support 🩵 Donate to keep the magic going 🪄✨ #Nephsky
020
Cristina Popa @nephroseeker.medsky.social · 28/08/2026
After three decades without a CKD-pregnancy trial, ORCHARD-BEET is changing that- a multicenter beetroot juice intervention (nitric oxide), with strong feasibility and early signals of kidney and neonatal benefit #NephJC
061
Reposted by Cristina Popa
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 24/08/2026
Should we still tell kidney stone formers to drink more water? podcasts.apple.com/ca/podcast/f... @kidneyboy.bsky.social @captainchloride.bsky.social @vipvargh.bsky.social with stone experts
podcasts.apple.com
FF95 The PUSH Trial
Podcast Episode · Freely Filtered, a NephJC Podcast · August 23 · 1h 6m
1116
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 21/08/2026
When our patients start HD, everything gets filtered, except the debate on beta-blocker dialyzability Read #NephJC short about the new target emulation trial, suggesting the non-dialyzables may be doing some heavy MACE-lifting ✍️By @drpallaviprasad.bsky.social nephjc.com/news/targetr...
nephjc.com
Is this the end of the beta-blocker debate in hemodialysis? — NephJC
This week, we will discuss
033
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 11/08/2026
🆕 #NephJC short by @brianrifkin.bsky.social 👏 APPLAUSE for iptacopan in IgA nephropathy- final eGFR results at 24 months 👀🔎 Read more www.nephjc.com/news/2026/sh...
nephjc.com
NephJC Short: 24-Month Iptacopan eGFR Data in IgA Nephropathy — NephJC
Iptacopan decreases proteinuria, now we get the 24-month eGFR data in patients with IgA Nephropathy.
083
Reposted by Cristina Popa
Arvind (Canchi) Conjeevaram @arvindcanchi.bsky.social · 07/08/2026
Follow the Kidney International Case Reports Journal on Instagram at ki_case_reports for some very interesting case reports! @hswapnil.medsky.social www.instagram.com/ki_case_repo...
instagram.com
Official Journal of the ISN (@ki_case_reports) • Instagram
385 Followers - 13 Posts - "Showcase the Power of Visual Learning with KICR’s Images in Nephrology Some of the most valuable lessons in nephrology …"
073
Reposted by Cristina Popa
kireports.bsky.social @kireports.bsky.social · 07/08/2026
#Clinical and #Histopathologic Spectrum of Primary #Nonfunction in Renal #Allografts #VisualAbstract by Cristina Popa www.kireports.org/article/S2468-024…
001
Reposted by Cristina Popa
ASN Publications @asnpublications.bsky.social · 05/08/2026
Is it time for clinicians to rethink “fistula first” for every older dialysis patient? The best access may be the one that aligns with the patient’s health, priorities, and quality of life, according to new research published in #ASNJASN. kidney.pub/JASN1160?... @hswapnil.bsky.social
022
Reposted by Cristina Popa
kireports.bsky.social @kireports.bsky.social · 04/08/2026
10-year Trends in #HeartFailure among Patients with #Dialysis and Non-dialysis #CKD #VisualAbstract by Husam Alzayer www.kireports.org/article/S2468-024…
011
Reposted by Cristina Popa
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 31/07/2026
Guidance on nutrition supplementation in dialysis www.kireports.org/article/S246... In @kireports.bsky.social Increasing protein intake once dialysis begins is important!
Algorithm
1119
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 31/07/2026
Summer's almost over 😎 #NephSky We know you've been waiting 🏖️ #NephJC Summer Book Club, 9/15/26 discussion! Salama Kassab was a pharmacy student in Syria. Now she helps the wounded who flood through the doors. Set amid the Syrian Revolution, a story of hope, love & possibility.
066
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 21/07/2026
Want more?? #NephSky #NephJC 🩳FIND-CKD shorts from @CristinaDeReins Finerenone in glomerulonephritis & a pooled analysis of safety and efficacy in CKD (INFINITY) www.nephjc.com/news/2026/7/20/finerenone-shorts
nephjc.com
Finerenone across the proteinuric CKD spectrum — NephJC
Cristina Popa dissects the FIND-CKD extras: GN subgroup and INFINITY analysis
077
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 22/07/2026
I want more info: www.nephjc.com/news/2026/7/... www.nephjc.com/news/2026/7/... @manoleaandreea.bsky.social @divyaveerssneph.bsky.social @rnflex.bsky.social @drbarbateba.bsky.social 9/10
nephjc.com
Finerenone across the proteinuric CKD spectrum — NephJC
Cristina Popa dissects the FIND-CKD extras: GN subgroup and INFINITY analysis
192
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 21/07/2026
👀 Seek and you shall FIND 🔎 #ERA26 #NephSky FIND-CKD asks if finerenone is beneficial in patients with non-diabetic CKD. Blog by @manoleaandreea.bsky.social & @divyaveerssneph.bsky.social www.nephjc.com/news/2026/7/6/find-ckd
nephjc.com
Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role — NephJC
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effect...
0106
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 12/07/2026
#NephJC Shorts is our new way to share quick takes on notable studies we can’t cover fully 👇👇Check the updated blog page for upcoming Shorts and those already published ✨Suggestions and feedback welcome www.nephjc.com/nephjc-shorts
nephjc.com
NephJC Shorts — NephJC
055
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 08/07/2026
#NephJC #TenPostNephJC. #NephSky 1/10 Patients with CKD have ⬆️ CVD & bleeding risks but are often excluded from antithrombotic trials, creating a 🔑 evidence gap. Can low dose rivaroxaban safely improve CV outcomes? pubmed.ncbi.nlm.nih.gov/42240165/
143
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 06/07/2026
🚆 TRACK trial: If thrombosis is at the core of 🫀disease...then DOACs might be helpful in high-risk CKD pts? Maybeeeee... #Nephsky Blog by @nephroseeker.medsky.social & @drsaivani.bsky.social www.nephjc.com/news/2026/7/6/on-the-right-track-rivaroxaban-to-prevent-cardiovascular-events-in-advanced-ckd
nephjc.com
On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD. — NephJC
Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD. Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown ben...
043
Reposted by Cristina Popa
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/07/2026
A #NephJC short of the telitacicept trial from @nephromommy-akshu.bsky.social www.nephjc.com/news/2026/sh... IMO the exciting part of the early signal of GFR stabilization - if this is recapitulated with atacicept and sibeprelimab - then we can truly say IgAN remission is here and achievable
nephjc.com
NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial) — NephJC
Does Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?
152
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 05/07/2026
Meeting number 2 is in the books. 🧑‍🏫We reviewed how to blog, create a VA, create a post thread and promote on Insta. So many ways to learn and teach #NephJC #NephSky @dramiliflores.bsky.social @drpallaviprasad.bsky.social @nephroseeker.medsky.social @hswapnil.medsky.social @brianrifkin.bsky.social
043
Reposted by Cristina Popa
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 03/07/2026
The second issue of the journal is live! @theisn.org @arvindcanchi.bsky.social Thanks to the authors, and our reviewers! Everything open access to read: www.kicasereports.org/issue/S3117-... #KICR
Journal logo
0123
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 02/07/2026
🧂New @freelyfiltered.bsky.social episode on hyponatremia correction #NephJC 🍾How can Brussels champagne help with hypoNa? 🎙️ Special invites: Ewot Hoorn @bettercallseeth.bsky.social 🎙️Filtrate: @kidneyboy.bsky.social @hswapnil.medsky.social @nephcrit.bsky.social www.nephjc.com/freelyfilter...
nephjc.com
FF93 Hyponatremia Interventional Trial — NephJC
Time to fix the sodium! The Hyponatremia Intervention Trial
184
Reposted by Cristina Popa
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 29/06/2026
And @nejm.org retracts ADVOCATE based on the FDA uncovering and 2 academic authors asking for article to be pulled. (Good on them!) www.nejm.org/doi/10.1056/... h/t @drjmluther.bsky.social #Avacopan #vasculitis
nejm.org
Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609. | NEJM
The two academic authors of the article by Jayne et al., Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609,1 request retraction of the article because, accordi...
11810
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 28/06/2026
🦵Had our Kick-off meeting today to welcome a new class of #NephJC interns (year 12 and counting). 👁️Keep an eye out for new blog and VA creators. See if you can Catch'em All🎣 #NephSky #MedSky @hswapnil.medsky.social @kidneyboy.bsky.social @nephroseeker.medsky.social @dramiliflores.bsky.social
088
Cristina Popa @nephroseeker.medsky.social · 26/06/2026
💡Nephrology inpatient volume increased 44%, outpacing other specialties ⏮️ Retrospective, 62 million admissions over 10 yrs 📍Patients became more complex: ⬆️multidisciplinary care, frailty& poorer primary care access 📍Complexity increased mainly independent of aging www.ajkd.org/article/S027...
031
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 23/06/2026
El resumen visual: MAJESTRY trial 👑 @dramiliflores.bsky.social and Dr. Divya Bajpai www.nephjc.com/news/ensayomajesty #NephSky #NephJC
nephjc.com
Majesty: El Resumen Visual — NephJC
Recién llegado desde #ERA26, el estudio MAJESTY comparó obinutuzumab frente a tacrolimus y plantea importantes interrogantes sobre el futuro de las terapias anti-CD20 en la nefropatía membranosa prima...
032
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 24/06/2026
#NephJC Consensus From GEMRITUX, MENTOR, STARMEN, RI-CYCLO & MAJESTY- the signal remains consistent: ✅ Anti-CD20 therapy works ✅ Remissions are durable ✅ Relapses are lower than CNIs Check out anti-CD20 trials in pMN by @nephroseeker.medsky.social 👇 #NephJC #TenPostNephJC #NephTwitter #NephSky
182
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 24/06/2026
2/10 What'd I miss? 👀 📍Obinutuzumab: type II anti-CD20 monoclonal antibody, depletes B cells 📍Tacrolimus: ⬇️ T lymphocytes through FK50-binding protein 📍MAJESTY asks: 👑 Can OBI outperform TAC in durable remission while preserving kidney function? #ChatGPT #NephJC #TenPostNephJC #NephSky
161
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 24/06/2026
1/10 With the incredible wave of glomerular disease and trials showcased at #ERA26, it's time for membranous nephropathy to take the stage Could deeper B-cell depletion finally claim the throne? 👑 Read the article 👇 pubmed.ncbi.nlm.nih.gov/42246654/ #NephJC #TenPostNephJC #NephSky
163
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 23/06/2026
The MAJESTRY trial, OBI vs TAC in membranous nephropathy. 👑 Visual abstract by Dr. Divya Bajpai #NephSky #NephJC www.nephjc.com/news/majestytrial
nephjc.com
Majesty: The Visual Abstract — NephJC
Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy. 👑 Is deeper B-cell d...
085
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 22/06/2026
Is it time for a new leader in membranous nephropathy, or is it just a game of thrones 👑? This week we're discussing OBI vs TAC in the MAJESTRY trial from #ERA26 🏰🐑 #NephSky We welcome back from retirement @jamiekwillows.bsky.social with the summary ✍️ www.nephjc.com/news/2026/06/22-majestyobi
nephjc.com
Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial — NephJC
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
01210
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 21/06/2026
🚨New 🩳 by @nephroseeker.medsky.social eGFRcr, eGFRcys, eGFRcr-cys, mGFR... What does mGFR teach us about estimates and outcomes? #NephSky #MedSky #NephJC www.nephjc.com/news/2026/short/measuredgfr
nephjc.com
NephJC Short: The map and the territory: what measured GFR teaches us about our estimates — NephJC
Is measured GFR more accurate than eGFR for forecasting adverse outcomes?
0149
Reposted by Cristina Popa
Brendon Neuen @brendonneuen.bsky.social · 18/06/2026
PowerPoint slides for the FIND-CKD primary presentation and NOW freely available – including the glomerular disease, data and INFINITY (IPD meta-analysis). Use them, adapt them, share them as you like - All FIND-CKD program presentations and publications now live at www.find-CKD.com
0102
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 03/06/2026
#TenPostNephJC #NephSky #NephJC 1/10 How often do we miss non-diabetic kidney disease (NDKD)? 🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash @glombandit.bsky.social kidney-international.org/article/S008...
186
Cristina Popa @nephroseeker.medsky.social · 02/06/2026
Here the #ERA26 starts! ❤️🫶Perfect welcome and room view for kidney docs
010
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 28/05/2026
✨Exciting news #NephtSky The new #NephJC editorial interns are here! 📢Give them a follow and make them feel at home 👉 @drbarbateba.bsky.social @ancast13.bsky.social @kiddokidney.bsky.social @andrewdelaat.bsky.social @farahwehbe92.bsky.social 👇👇 www.nephjc.com/news/2025/6/...
nephjc.com
NephJC Internship 2026-2027 — NephJC
Introducing NephJC’s brand new editorial internship class of 2026-2027
11912
Reposted by Cristina Popa
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 25/05/2026
save the date the 2027 #ISNWCN @theisn.org will be in Kuala Lumpur #NephSky
formal announcement
WCN 2027 changed from Dubai to Kuala Lumpur
1102
Reposted by Cristina Popa
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 23/05/2026
The LBCT line up at #ERA26 next week Day 1: TRACK is the big one (rest is phase 2 or results we know) Day 2 is FIND CKD, TURING & MAJESTY sound interesting Day 3: GOOD IDES is negative, Ravulizumab is positive 1; HDx will torture something positive I think Lots of FOMO on missing Glasgow
LBCT 1LBCT 2High impact 1High impact 2
1153
Reposted by Cristina Popa
kireports.bsky.social @kireports.bsky.social · 20/05/2026
1/ Hey #NephSky #MedSky 👋👋 Could a very high eGFR be a warning sign, not reassurance? This #KIreports editorial reframes "supra-normal" filtration as early cardiorenal stress and makes the case for a next-generation heat map www.kireports.org/article/S246...
142
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 20/05/2026
11/10 Up next: Clinical and histologic predictors of non-diabetic kidney disease in patients with diabetes mellitus www.kidney-international.org/article/S008... This has been Dr. Priya John with another 10 posts Join us at www.nephjc.com
kidney-international.org
Clinical and histologic predictors of non-diabetic kidney disease in patients with diabetes mellitus
The number of kidney biopsies performed in patients with diabetes has increased rapidly over the last two decades. However, the overall value of the biopsy has been questioned because any coexisting n...
031
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 20/05/2026
#NephJC #TenPostNephJC. #NephSky 1/10 Building on the landmark findings of the SBP Intervention Trial, this study shows that team-based HTN care can successfully translate intensive BP control into meaningful CV benefits for underserved, low-income communities. pubmed.ncbi.nlm.nih.gov/41950472/
154
Reposted by Cristina Popa
Nephrology Journal Club @nephjc.bsky.social · 20/05/2026
9/10 I want more info Blog by @nephromommy-akshu.bsky.social @nephroseeker.medsky.social www.nephjc.com/news/2026-impact-bp VA by @nephromommy-akshu.bsky.social www.nephjc.com/news/2026/5/18/impacts-bp-the-visual-abstract
nephjc.com
IMPACTS-BP: The Visual Abstract — NephJC
Can multifaceted strategies improve hypertension control in low-income patients? Hypertension remains one of the leading cardiovascular risk factors worldwide. However, achieving adequate blood press...
232
Cristina Popa @nephroseeker.medsky.social · 18/05/2026
#NephJC
010
Reposted by Cristina Popa
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 15/05/2026
On that note: the preceding EUPHRATES (from which the subgroup was picked for the priors) was sham controlled - we were a site and it was nicely done pmc.ncbi.nlm.nih.gov/articles/PMC... Also note there is little overlap in between the academic lead authors for EUPHRATES and TIGRIS 😎
pmc.ncbi.nlm.nih.gov
Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial
Does polymyxin B hemoperfusion improve survival in patients with septic shock and high levels of endotoxin in the blood? In this multicenter, randomized, clinical trial that included 450 adults with s...
131